Abstract
Patients participating in clinical trials are highly selected and may not represent the general population. The pivotal study of teclistamab (MajesTEC-1), a B-cell maturation antigen (BCMA)xCD3 bispecific antibody, demonstrated impressive response rates and progression free survival in relapsed/refractory multiple myeloma (RRMM) with acceptable toxicity. We performed a retrospective study of 58 patients treated as standard of care at four US academic centers to determine how these results translated to the real-world. Most patients (87.9%) would not have been eligible for the MajesTEC-1 study due to either disease related factors, patient related comorbidities or socio-economic/geographical factors. Despite these ‘less-favorable’ characteristics we observed similar efficacy and toxicity to MajesTEC-1. A meta-analysis with six other published real-world series (n = 546) confirmed these results. These data support the significant clinical activity of teclistamab in RRMM and highlights the importance of real-world data to accompany the pivotal trial data to further inform daily clinical practice.
| Original language | English |
|---|---|
| Pages (from-to) | 942-951 |
| Number of pages | 10 |
| Journal | Leukemia and Lymphoma |
| Volume | 66 |
| Issue number | 5 |
| DOIs | |
| State | Published - 2025 |
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Keywords
- RRMM
- bispecific antibody
- multiple myeloma
- real-world
- relapsed/refractory
- teclistamab
